NCT02225288View on ClinicalTrials.gov

A Study of E2022 Tape Formulation (Overlay-integrated E2022 18 mg Tape Formulation) for Different Application Sites and Intervals in Japanese Healthy Elderly Males

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

February 28, 2015

Conditions
Healthy Subjects
Interventions
DRUG

E2022

transdermal E2022 tape formulation (8.1 cm x 8.1 cm)

Trial Locations (1)

Unknown

Kagoshima

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY

NCT02225288 - A Study of E2022 Tape Formulation (Overlay-integrated E2022 18 mg Tape Formulation) for Different Application Sites and Intervals in Japanese Healthy Elderly Males | Biotech Hunter | Biotech Hunter